Hyperprolactinemia: When Prolactin Levels Go Too High
Prolactin is a hormone that most people associate exclusively with breastfeeding, and while that is its most well-known function, prolactin does far more than stimulate milk production. It plays roles in immune regulation, reproductive function, and metabolic processes in both men and women. When prolactin levels become chronically elevated, a condition called hyperprolactinemia, the effects ripple across multiple body systems and can cause symptoms that significantly impact quality of life. This video provides a thorough breakdown of the causes, symptoms, diagnosis, and treatment of this condition.
Prolactin is produced by lactotroph cells in the anterior pituitary gland, and its secretion is primarily regulated by dopamine from the hypothalamus. Dopamine acts as a brake on prolactin production. When dopamine signaling is reduced, whether through medication, tumors, or other causes, the brake comes off and prolactin levels rise. This dopamine-prolactin relationship is central to understanding both the causes and treatments of hyperprolactinemia.
Normal prolactin levels in non-pregnant, non-lactating adults are typically below 25 ng/mL in women and below 20 ng/mL in men, though reference ranges vary between labs. Levels above these thresholds warrant investigation, and the degree of elevation often provides clues about the underlying cause.
Common Causes: From Medications to Tumors
The single most common cause of elevated prolactin is medication. A surprisingly long list of drugs can raise prolactin by blocking dopamine receptors or reducing dopamine activity. Antipsychotic medications (both typical and atypical, including risperidone, haloperidol, and olanzapine) are the most frequent offenders. Certain antidepressants (SSRIs), anti-nausea medications (metoclopramide, domperidone), and some blood pressure medications can also elevate prolactin. For anyone with newly discovered hyperprolactinemia, a thorough medication review is the first diagnostic step.
Prolactinomas, which are benign pituitary tumors that produce prolactin, are the most common pituitary tumor type. They range from microprolactinomas (less than 10 mm in diameter) to macroprolactinomas (10 mm or larger). The prolactin level often correlates with tumor size: microprolactinomas typically produce prolactin levels of 50-200 ng/mL, while macroprolactinomas can produce levels in the thousands. This correlation is useful diagnostically, as a prolactin level above 200-250 ng/mL in the setting of a pituitary mass strongly suggests a prolactinoma rather than a non-functioning tumor that is compressing the stalk.
Hypothyroidism is another cause that deserves attention. When thyroid hormone is low, TRH (thyrotropin-releasing hormone) from the hypothalamus increases, and TRH stimulates both TSH and prolactin release. Treating the hypothyroidism typically normalizes prolactin without any additional intervention, making thyroid function testing essential in the workup of any patient with elevated prolactin.
Other Causes Worth Considering
Stalk effect occurs when a mass near the pituitary (not necessarily a prolactinoma) compresses the pituitary stalk, disrupting the flow of dopamine from the hypothalamus to the pituitary. Without dopamine's inhibitory effect, prolactin rises. This distinction matters because stalk-effect hyperprolactinemia is treated differently than prolactinomas. The prolactin levels in stalk effect are usually modest (25-100 ng/mL), which helps distinguish it from a true prolactinoma.
Chronic kidney disease, liver cirrhosis, chest wall irritation (herpes zoster, post-surgical), and even significant stress or intense exercise can mildly elevate prolactin. These causes are usually identified through clinical context and produce modest elevations that resolve when the underlying condition is addressed.
One diagnostic pitfall is the "hook effect" with macroprolactinomas. When prolactin levels are extremely high (sometimes above 10,000 ng/mL), standard lab assays can actually report a falsely normal or mildly elevated result due to antibody saturation in the assay. If a large pituitary tumor is present but prolactin comes back only mildly elevated, requesting a serial dilution can unmask the true level and avoid misdiagnosis.
Signs and Symptoms Across Both Sexes
In women, the most common presentation is menstrual irregularity or amenorrhea (absent periods). Prolactin suppresses GnRH (gonadotropin-releasing hormone) from the hypothalamus, which in turn suppresses FSH and LH, leading to anovulation and estrogen deficiency. This is the same mechanism that suppresses fertility during breastfeeding. Women may also experience galactorrhea (inappropriate milk discharge from the breasts), infertility, decreased libido, vaginal dryness, and if the hyperprolactinemia is prolonged, bone density loss from chronic estrogen depletion.
In men, hyperprolactinemia causes hypogonadism through the same GnRH suppression mechanism. Symptoms include decreased libido, erectile dysfunction, fatigue, loss of muscle mass, and potentially gynecomastia (breast tissue development). Because these symptoms are nonspecific and overlap with many other conditions, hyperprolactinemia in men is often diagnosed late, frequently only after a macroprolactinoma has grown large enough to cause visual field deficits from optic chiasm compression.
In both sexes, large prolactinomas can cause headaches and visual disturbances due to the tumor's physical proximity to the optic chiasm. The classic visual field deficit is bitemporal hemianopia, loss of peripheral vision on both sides, though the specific pattern depends on exactly how the tumor compresses the visual pathways.
Diagnosis and Workup
The diagnostic workup for hyperprolactinemia includes confirming the elevation with a repeat measurement (since prolactin can be transiently elevated by stress, recent breast stimulation, or even the blood draw itself), checking thyroid function, reviewing medications, testing renal and liver function, and obtaining an MRI of the pituitary with gadolinium contrast if no other cause is identified. The MRI is the gold standard for visualizing pituitary anatomy and identifying prolactinomas or other structural causes.
Visual field testing (formal perimetry) should be performed for anyone with a macroadenoma, as it establishes a baseline and helps track whether the tumor is affecting the optic pathways. Additional pituitary hormone testing (cortisol, IGF-1, TSH, free T4, LH, FSH, testosterone or estradiol) assesses whether the tumor is affecting the function of other pituitary cell types.
Treatment Approaches
For medication-induced hyperprolactinemia, the first approach is to work with the prescribing provider to determine whether the offending medication can be switched or discontinued. In psychiatric patients, this requires careful risk-benefit analysis, as the antipsychotic medication may be essential for mental health stability. Aripiprazole, an atypical antipsychotic with partial dopamine agonist properties, may be an alternative that produces less prolactin elevation.
For prolactinomas, medical therapy with dopamine agonists is the first-line treatment, not surgery. Cabergoline (Dostinex) is the preferred agent due to its superior efficacy, fewer side effects, and convenient twice-weekly dosing compared to the older drug bromocriptine. Cabergoline normalizes prolactin in approximately 85-90% of patients and shrinks the tumor in the majority of cases, sometimes dramatically. Some macroprolactinomas shrink by 50% or more within weeks of starting treatment.
Surgery (transsphenoidal adenomectomy) is reserved for patients who do not respond to medical therapy, cannot tolerate dopamine agonists, or have complications like cerebrospinal fluid leakage or acute visual deterioration. Radiation therapy is a third-line option for refractory cases.
Monitoring during treatment includes regular prolactin measurements, periodic MRI scans to assess tumor size, and visual field testing for macroprolactinomas. Once prolactin has normalized and the tumor has shrunk on stable medical therapy for at least two years, some patients can attempt dose reduction or discontinuation under close surveillance, as a significant minority (around 30%) remain in remission after stopping cabergoline.
Living With Hyperprolactinemia: Long-Term Considerations
For patients diagnosed with prolactinomas, the long-term outlook is generally favorable. Most microprolactinomas remain stable or even shrink with medical therapy, and many patients achieve normal prolactin levels and full symptom resolution on cabergoline. The question of how long to continue therapy is individualized. Some patients require lifelong treatment, while others can successfully discontinue medication after 2-3 years of normalized prolactin and documented tumor shrinkage.
Bone health monitoring is important for anyone who has had prolonged hyperprolactinemia-induced hypogonadism. The estrogen or testosterone deficiency that results from prolactin suppressing GnRH can lead to meaningful bone density loss if the condition persists for years without treatment. A baseline DEXA scan at diagnosis and periodic follow-up scans help assess whether bone density is recovering with treatment or whether additional interventions (calcium, vitamin D, weight-bearing exercise, or potentially bisphosphonates) are needed.
Pregnancy planning requires special attention in women with prolactinomas. Cabergoline is generally discontinued once pregnancy is confirmed (unless the tumor is large and poses a risk of symptomatic growth during pregnancy). Prolactinomas can enlarge during pregnancy due to the estrogen-driven stimulation of lactotroph cells, so women with macroprolactinomas need closer monitoring during pregnancy, including visual field testing each trimester, than those with microprolactinomas.
The psychological impact of hyperprolactinemia extends beyond the direct hormonal symptoms. Dealing with a pituitary condition, managing ongoing medication, undergoing periodic MRI scans, and living with the uncertainty of whether the tumor will recur after treatment discontinuation can create anxiety and emotional burden. Mental health support should be part of the thorough management plan, not an afterthought. Many pituitary tumor support groups exist online and can provide community and practical advice from people who understand the experience firsthand.
For men, the delayed diagnosis pattern deserves emphasis. Because the symptoms of hypogonadism in men (fatigue, low libido, erectile issues) are so nonspecific, prolactinomas in men are frequently diagnosed later and at larger sizes than in women. Any man presenting with hypogonadal symptoms and no clear cause should have a prolactin level checked as part of the initial workup. This simple, inexpensive test can prevent years of misdiagnosis and the complications that come with growing, untreated pituitary tumors.